Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361954304> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W4361954304 abstract "<div>AbstractPurpose:<p>Anti–programmed cell death-1 monotherapy is part of standard therapy for cutaneous melanoma but has low efficacy in mucosal melanoma. We evaluated the efficacy and safety of atezolizumab plus bevacizumab as first-line therapy for advanced mucosal melanoma.</p>Patients and Methods:<p>This multicenter, open-label, single-arm, phase II study used a Simon's two-stage design. Atezolizumab (fixed-dose, 1,200 mg) and bevacizumab (7.5 mg/kg) were administered by intravenous infusion every 3 weeks. The primary endpoint was objective response rate (ORR), determined per RECIST v1.1. Secondary endpoints included progression-free survival (PFS), overall survival (OS), duration of response (DOR), and safety, with adverse events (AE) summarized using NCI-CTCAE v5.0.</p>Results:<p>Overall, 43 patients were enrolled, including 20 (46.5%) with unresectable and 23 (53.5%) with metastatic mucosal melanoma. Median follow-up was 13.4 months at data cutoff (July 30, 2021). Forty patients were evaluable for response: ORR was 45.0% [95% confidence interval (CI), 29.3%–61.5%; one complete response, 17 partial responses]. Median PFS was 8.2 months (95% CI, 2.7–9.6); 6- and 12-month PFS rates were 53.4% (95% CI, 36.6%–67.6%) and 28.1% (95% CI, 14.2%–43.9%), respectively. Median OS was not reached (NR; 95% CI, 14.4–NR). Six- and 12-month OS rates were 92.5% (95% CI, 78.5%–97.5%) and 76.0% (95% CI, 57.1%–87.5%), respectively. Median DOR was 12.5 months (95% CI, 5.5–NR). Overall, 90.7% (39/43) of patients experienced treatment-related AEs; 25.6% (11/43) experienced grade ≥3 events.</p>Conclusions:<p>Atezolizumab in combination with bevacizumab showed promising efficacy and manageable safety in patients with advanced mucosal melanoma.</p></div>" @default.
- W4361954304 created "2023-04-05" @default.
- W4361954304 creator A5007562507 @default.
- W4361954304 creator A5008972554 @default.
- W4361954304 creator A5018372804 @default.
- W4361954304 creator A5030780445 @default.
- W4361954304 creator A5049502035 @default.
- W4361954304 creator A5054668748 @default.
- W4361954304 creator A5060265024 @default.
- W4361954304 creator A5068534965 @default.
- W4361954304 creator A5078810236 @default.
- W4361954304 creator A5079717865 @default.
- W4361954304 creator A5082114255 @default.
- W4361954304 creator A5084636770 @default.
- W4361954304 date "2023-04-01" @default.
- W4361954304 modified "2023-10-18" @default.
- W4361954304 title "Data from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study" @default.
- W4361954304 doi "https://doi.org/10.1158/1078-0432.c.6532724.v1" @default.
- W4361954304 hasPublicationYear "2023" @default.
- W4361954304 type Work @default.
- W4361954304 citedByCount "0" @default.
- W4361954304 crossrefType "posted-content" @default.
- W4361954304 hasAuthorship W4361954304A5007562507 @default.
- W4361954304 hasAuthorship W4361954304A5008972554 @default.
- W4361954304 hasAuthorship W4361954304A5018372804 @default.
- W4361954304 hasAuthorship W4361954304A5030780445 @default.
- W4361954304 hasAuthorship W4361954304A5049502035 @default.
- W4361954304 hasAuthorship W4361954304A5054668748 @default.
- W4361954304 hasAuthorship W4361954304A5060265024 @default.
- W4361954304 hasAuthorship W4361954304A5068534965 @default.
- W4361954304 hasAuthorship W4361954304A5078810236 @default.
- W4361954304 hasAuthorship W4361954304A5079717865 @default.
- W4361954304 hasAuthorship W4361954304A5082114255 @default.
- W4361954304 hasAuthorship W4361954304A5084636770 @default.
- W4361954304 hasBestOaLocation W43619543042 @default.
- W4361954304 hasConcept C121608353 @default.
- W4361954304 hasConcept C126322002 @default.
- W4361954304 hasConcept C141071460 @default.
- W4361954304 hasConcept C143998085 @default.
- W4361954304 hasConcept C197934379 @default.
- W4361954304 hasConcept C203092338 @default.
- W4361954304 hasConcept C2775949291 @default.
- W4361954304 hasConcept C2776694085 @default.
- W4361954304 hasConcept C2777658100 @default.
- W4361954304 hasConcept C2777701055 @default.
- W4361954304 hasConcept C2777802072 @default.
- W4361954304 hasConcept C2779984678 @default.
- W4361954304 hasConcept C2780057760 @default.
- W4361954304 hasConcept C2780739268 @default.
- W4361954304 hasConcept C31760486 @default.
- W4361954304 hasConcept C44249647 @default.
- W4361954304 hasConcept C502942594 @default.
- W4361954304 hasConcept C535046627 @default.
- W4361954304 hasConcept C71924100 @default.
- W4361954304 hasConcept C90924648 @default.
- W4361954304 hasConceptScore W4361954304C121608353 @default.
- W4361954304 hasConceptScore W4361954304C126322002 @default.
- W4361954304 hasConceptScore W4361954304C141071460 @default.
- W4361954304 hasConceptScore W4361954304C143998085 @default.
- W4361954304 hasConceptScore W4361954304C197934379 @default.
- W4361954304 hasConceptScore W4361954304C203092338 @default.
- W4361954304 hasConceptScore W4361954304C2775949291 @default.
- W4361954304 hasConceptScore W4361954304C2776694085 @default.
- W4361954304 hasConceptScore W4361954304C2777658100 @default.
- W4361954304 hasConceptScore W4361954304C2777701055 @default.
- W4361954304 hasConceptScore W4361954304C2777802072 @default.
- W4361954304 hasConceptScore W4361954304C2779984678 @default.
- W4361954304 hasConceptScore W4361954304C2780057760 @default.
- W4361954304 hasConceptScore W4361954304C2780739268 @default.
- W4361954304 hasConceptScore W4361954304C31760486 @default.
- W4361954304 hasConceptScore W4361954304C44249647 @default.
- W4361954304 hasConceptScore W4361954304C502942594 @default.
- W4361954304 hasConceptScore W4361954304C535046627 @default.
- W4361954304 hasConceptScore W4361954304C71924100 @default.
- W4361954304 hasConceptScore W4361954304C90924648 @default.
- W4361954304 hasLocation W43619543041 @default.
- W4361954304 hasLocation W43619543042 @default.
- W4361954304 hasOpenAccess W4361954304 @default.
- W4361954304 hasPrimaryLocation W43619543041 @default.
- W4361954304 hasRelatedWork W2037355330 @default.
- W4361954304 hasRelatedWork W2249259383 @default.
- W4361954304 hasRelatedWork W2894779831 @default.
- W4361954304 hasRelatedWork W3041755538 @default.
- W4361954304 hasRelatedWork W3170784747 @default.
- W4361954304 hasRelatedWork W4224311543 @default.
- W4361954304 hasRelatedWork W4281653420 @default.
- W4361954304 hasRelatedWork W4293785955 @default.
- W4361954304 hasRelatedWork W4361950469 @default.
- W4361954304 hasRelatedWork W4361954304 @default.
- W4361954304 isParatext "false" @default.
- W4361954304 isRetracted "false" @default.
- W4361954304 workType "article" @default.